Two phosphAte taRGets in End-stage Renal Disease Trial (TARGET)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 104 participants.

Also called NCT01994733

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 104 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01994733
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01994733. Randomized; no masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Two phosphAte taRGets in End-stage Renal Disease Trial (TARGET)
Acronym
TARGET
Condition
End-stage Renal Disease
Intervention (Drug)
Calcium carbonate ( Intensive phosphate control)
Intervention (Drug)
Calcium carbonate (Liberalized phosphate control)
Lead sponsor
Unity Health Toronto (class: other)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)

Record details

Record id
cardio:ct-nct01994733
Content hash
1569f0fa5549b2ce67fa2825e26b469a90b45fbc919ff67bc078656647750708